Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years
Related reading
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022